Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | Orlistat | Sibutramine |
|---|---|---|
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
| - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Sources
Release date
May 2021
More information
Region
United Kingdom (England)
Survey time period
2002 to 2020
Supplementary notes
* Prescribed in primary care and dispensed in the community.
The Net Ingredient Cost (NIC) is the basic cost of a drug.
On January 21st 2010, the European Medicines Agency (EMA) released a statement advising the suspension of Sibutramine. Therefore, data on Sibutramine will be limited for 2010-2012.
In 2012, there was a shortage of the drug Orlistat due to a disruption to the manufacturing of supply.
Citation formats
